---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-024370"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2023-08-22T23:59:59+00:00"
generated_at: "2026-06-11T05:30:47.800614+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vistagen appoints Cindy Anderson as CFO; Jerrold Dotson retires after decade-long tenure

## Summary
- Cindy Anderson appointed CFO effective August 21, 2023, succeeding Jerrold Dotson upon his planned retirement.
- Anderson brings 15+ years biopharma experience, most recently Chief Accounting Officer at Alnylam Pharmaceuticals (ALNY).
- She previously held senior finance roles at Alexion Pharmaceuticals and began her career at PwC and EY.
- No arrangements or related-party transactions exist in connection with Anderson's appointment.
- CEO Shawn Singh expressed gratitude for Dotson's decade of service and welcomed Anderson's financial expertise.

## SEC filing metadata
- accession: 0001437749-23-024370
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2023-08-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000143774923024370/0001437749-23-024370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000143774923024370/vtgn20230821_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-024370
- JSON: https://secwatch.observer/filing/0001437749-23-024370.json
- Plain text: https://secwatch.observer/filing/0001437749-23-024370.txt

## Key facts
- Executive change
  Cynthia Anderson was appointed as Chief Financial Officer at Vistagen Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: announced the appointment of Ms. Cynthia Anderson, C.P.A., as the Company’s Chief Financial Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000143774923024370/0001437749-23-024370-index.htm
- Executive change
  Jerrold Dotson retired as Chief Financial Officer at Vistagen Therapeutics, Inc..
  - Action: retired
  - Role: Chief Financial Officer
  source text: Ms. Anderson replaces Mr. Jerrold Dotson upon his retirement, effective August 21, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000143774923024370/0001437749-23-024370-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.